Connect Biopharma to present data on rademikibart for asthma and COPD at ATS 2025, initiating Phase 2 trials in 2025. Connect Biopharma Holdings Limited announced its plans to present four posters at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback